Yi-Ju Ko

Title: Yi-Ju Ko: Innovator in Antibody-Drug Conjugates

Introduction

Yi-Ju Ko is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of antibody-drug conjugates (ADCs). With a total of 4 patents to his name, his work is paving the way for innovative treatments in cancer therapy.

Latest Patents

Yi-Ju Ko's latest patents include groundbreaking advancements in linker-drug and antibody-drug conjugate technologies. One of his notable patents describes a linker-drug represented by a specific formula, which includes a conjugator, linker unit, and toxin unit. This invention allows for the conjugation of an antibody to the linker unit through a cysteine residue, enhancing the efficacy of the drug. Another significant patent focuses on the method for forming an antibody-drug conjugate, detailing the components involved and the process of conjugation.

Career Highlights

Yi-Ju Ko is affiliated with the Industrial Technology Research Institute, where he continues to innovate in the field of drug development. His research has been instrumental in advancing the understanding and application of ADCs, which are crucial in targeted cancer therapies.

Collaborations

Some of his notable coworkers include Maggie Lu and Ping-Fu Cheng, who contribute to the collaborative efforts in research and development within their institution.

Conclusion

Yi-Ju Ko's work in the field of antibody-drug conjugates exemplifies the innovative spirit of modern biopharmaceutical research. His contributions are vital for the future of targeted therapies, and his patents reflect a commitment to advancing medical science.